In the future, whether to use EGFR inhibitors such as erlotinib (Tarceva®) and gefitinib (Iressa®) for targeting AREG and decreasing long-term exposure to PM-induced lung cancer patients is worthy of further study. This evidence concerns the gene AREG and lung carcinoma.